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Richard P Steeds MA MD FRCP FESC
Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
It was a pleasure to welcome delegates to the annual 
conference of the British Society of Echocardiography 
(BSE) in November 2016. This was held at the prestigious 
Queen Elizabeth II Conference Centre in the City 
of London, with fabulous views directly out over 
Westminster Cathedral and the Houses of Parliament. 
There was an extremely full and varied program over 
2 days meaning that delegates had little time to go sight-
seeing! The numbers of delegates attending the conference 
has increased every year and 2016 was no exception, with 
almost a thousand delegates and 26 exhibitors, including 
representatives from all the major echocardiography 
companies. Lectures were spread over three auditoria 
during the conference, with parallel sessions meaning 
that there were plenty of options from which to choose. 
In addition, there were practical training sessions using 
simulators for hands-on experience, and live discussions 
during the breaks on hot topics in echocardiography, 
both technical and societal.
In this supplement for Echo Research and Practice, we 
have summarized some of the highlights of the conference. 
These include the invited lecture from our national 
speaker, Prof. Martin Cowie who proved incredibly popular 
with the delegates. We have also summarized the lectures 
that were given in the session sponsored by Echo Research 
and Practice. These lectures were by leaders in their field 
and are a reflection of the high-quality, evidence-based 
research and practice that is presented at our conference 
and that makes up the contents of the journal. Finally, 
we have included some of the high-quality abstracts 
that were presented during the conference. For the main 
abstract session, this includes the winning abstract by 
Janaki Srinivasan, investigating deformation changes that 
occur in Takutsubo cardiomyopathy. In support of our 
future researchers, we have included the abstracts from 
the Scientific Training Programme (STP) day, including 
the winning abstract from Dean Thomas.
The 2017 conference will take place on the 10th 
and 11th November in Edinburgh, at the Edinburgh 
International Conference Centre. We are delighted to 
welcome Allan Klein, current President of the American 
Society of Echocardiography, as our invited international 
speaker on Saturday 11th November 2017. We look 
forward to seeing you there!
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National Invited Lecture 2016
Martin R Cowie MD MSc FRCP FRCP(Ed) FESC
Imperial College London (Royal Brompton Hospital), London, UK
The heart failure epidemic: a UK perspective
There are more than half a million people living with 
heart failure (HF) in the United Kingdom, and the NHS 
spends 1–2% of its budget on this (60–70% related to the 
costs of hospitalization). Echocardiography is key to the 
diagnosis of HF, being the most readily available cardiac 
imaging modality.
In the most recently available data from the national 
(hospital) audit, echocardiography was performed in 
around 90% of hospitalized patients, with the use higher 
in those patients admitted to a cardiac ward (around 50% 
of patients) than those admitted to a more general ward. 
HF specialist nurses reach an additional 20% of patients.
The echocardiographic data collected in the national 
audit are not detailed, but it shows that 70% have obvious 
LV systolic dysfunction. Valve disease is very common 
(over 30% of cases), with isolated diastolic dysfunction 
recorded for around 10% of cases.
The National Institute for Health and Care Excellence 
(NICE) has issued clear guidance to the NHS in England 
as to what good care looks like for both chronic and acute 
(hospitalized) HF. It has also issued Quality Standards so 
that health care services, commissioners, patients and the 
public can judge the quality of care using a small number 
of carefully chosen metrics.
For chronic HF, people with suspected HF should 
have an echocardiogram and specialist assessment. If 
the patient has had a previous myocardial infarction or 
has a very high level of serum natriuretic peptides, then 
the echocardiogram and assessment need to be delivered 
within 2 weeks. NICE does not stipulate the location of 
the imaging, leaving this up to local services to determine 
whether community or hospital-based facilities are the 
more appropriate.
For acute (hospitalized) HF, new cases should have 
a measurement of natriuretic peptide in the emergency 
room or acute admissions unit, and if this elevated 
and HF is suspected then an echocardiogram should be 
performed within 48 h of admission. Also, such patients 
should have input from the specialist HF team within 24 h 
of admission.
Major issues remain regarding access to diagnostic 
tests in primary and secondary care, with huge variability 
from one part of the country to another. The All Party 
Parliamentary Group on Heart Disease has issued a report 
entitled ‘Focus on heart failure’. In its submission to that 
group of MPs and peers, the Alliance for Heart Failure 
highlighted the shortage of echocardiographers in the UK. 
The current manpower issues for echocardiography must 
be overcome if the NHS can deliver the quality of care that 
NICE, health care professionals and patients demand.
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Right ventricular function in  
tricuspid regurgitation
Bushra S Rana
The natural history and treatment of tricuspid regurgitation 
(TR) remains poorly understood. Right ventricular 
function is a key factor in determining prognosis, 
timing for intervention and longer-term outcome. Right 
ventricular (RV) morphology underpins RV function. 
The RV is a thin-walled chamber with a predominance 
of longitudinal fibers and a shared ventricular septum. 
In health, the low pressure system of the pulmonary 
circulation generates a highly compliant RV that is well 
equipped to respond to changes in preload but sensitive 
to even small alterations in afterload. Key principles of 
ventricular function assessment are emphasized and 
highlight the importance of RV size, volumes and ejection 
fraction, particularly in risk stratification in TR.
The paucity of published data reflects some 
uncertainty in the management of TR and timing of 
intervention. Historic data have suggested surgical 
treatment of TR carries high mortality. However, these 
data reflect the cohort studied, namely residual TR 
seen some years post mitral valve surgery. These data 
emphasize the importance of understanding the etiology 
of TR and defining more precisely RV dysfunction. Early 
surgery should be considered in primary severe TR with 
RV dilatation even prior to significant symptoms and 
emphasizes the importance of functional assessment 
and exercise contractile reserve. Functional severe TR 
represents a different cohort of patients who have 
pulmonary hypertension and/or primary RV dysfunction 
responsible for annular dilatation and severe secondary 
TR. Those presenting with RV failure reflect a potentially 
high-risk group with often complex disease, involving RV 
dysfunction, pulmonary hypertension and hepatic and 
renal complications, with additional pulmonary and left 
heart disease who may have undergone previous cardiac 
surgery. Careful assessment and work up are needed 
to ensure intervention is performed in a timely and 
appropriate manner.
The left ventricle in aortic stenosis
John B Chambers
The left ventricle (LV) responds to pressure load by 
myocyte hypertrophy, which is a means of minimizing 
increased wall stress. Unfortunately, this process is also 
accompanied by fibrosis and this is maladaptive. Left 
ventricular hypertrophy (LVH) is associated with an 
increased risk of adverse events before and after surgery. 
Left ventricular hypertrophy occurs gradually initially 
with concentric remodeling defined by a ratio of 2× 
posterior wall width to LV diastolic diameter >0.45. 
LVH occurs once a threshold LV mass index is exceeded, 
often taken as 109 g/m2 in women and 134 g/m2 in men. 
However, some patients develop asymmetric hypertrophy 
mainly affecting the septal and anteroseptal segments. 
Others develop LV cavity dilatation and hypokinesis at 
end-stage or relatively early in their natural history.
What determines these different patterns of LV 
response? The grade of valve obstruction only affects LV 
geometry and function in severe aortic stenosis. Systemic 
hypertension is also a major determinant particularly of 
asymmetric hypertrophy. Gender exerts an important 
effect. Women tend to develop thick-walled, but small 
LV cavities while men are more likely to develop thinner 
more dilated LV cavities. This may be because the pattern 
of collagen deposition is different between the two sexes. 
Coronary disease is associated with LV cavity dilatation 
and hypokinesis even with subsurgical disease. A genetic 
component is likely to explain about 30% of variability 
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in wall thickness in white and 40% in black patients. The 
nature of the genetic influence is still not known although 
the angiotensin-converting enzyme is a likely candidate. 
It is also possible that there is a relationship with 
hypertrophic cardiomyopathy, which is more common in 
relatives of patients with asymmetric hypertrophy than 
those without.
What is the clinical significance of this? The LV 
response is variable with severe LV systolic or diastolic 
dysfunction developing as a result of severe aortic stenosis 
in some patients but in the presence of more moderate 
aortic stenosis in others. At its most extreme is the 
situation of low gradient normal EF severe aortic stenosis 
where there are effectively two separate disease processes, 
HFPEF (heart failure with preserved ejection fraction) 
and aortic stenosis. This usually develops without the 
intermediate stage of high-gradient normal aortic stenosis 
and responds less well than usual to invasive therapy. To 
prevent this increasingly common entity, we probably 
need to treat systemic hypertension as a potential cause 
of LV dysfunction much earlier than we do now and using 
angiotensin-converting enzyme inhibitors.
Monitoring the heart during mitral 
regurgitation
Simon Ray
Severe primary mitral regurgitation (MR) imposes a 
state of volume overload on the left ventricle (LV). The 
ventricle is able to adapt to this state with an increase 
in end diastolic volume to accommodate the increased 
stroke volume of severe MR while maintaining a normal 
end-systolic wall stress. This phase of ‘compensated’ MR 
may be apparently stable for months or years but if the 
regurgitation continues unchecked then at some point 
left ventricular dilation becomes progressive, end-systolic 
volumes and wall stress begin to increase and ejection 
fraction to fall. It has been recognized for years that once 
this ‘decompensated’ phase is reached, or patients become 
significantly symptomatic, survival is reduced even if the 
valve is then repaired or replaced. Therefore, patients 
need to be referred for surgery before this stage is reached 
and echocardiography is used to monitor serial changes in 
the LV – the so-called ‘watchful waiting’ strategy.
Conventionally, end-systolic diameter and LV ejection 
fraction have been the principal measures used to identify 
incipient decompensation with end-systolic dimension 
(ESD) of ≥40 mm or an LV ejection fraction (EF) of ≤60% 
considered Class 1 indicators for surgery in reparable 
valves. The most recent guidelines from the American 
Heart Association/American College of Cardiology 
categorize asymptomatic patients in this phase as being in 
stage C2 of MR as distinct from stage C1 where individuals 
are asymptomatic with ESD of <40 mm and EF >60%. This 
is a useful conceptual model.
There is however some evidence that reliance on 
these simple parameters to refer patients for surgery 
may miss important degrees of LV dysfunction that only 
become apparent postoperatively when the MR has been 
abolished. Various methods have been used in an attempt 
to refine the identification incipient transition to stage 
C2. These include exercise echo, longitudinal function 
using speckle tracking to derive global longitudinal strain 
(GLS), left atrial function, cardiac magnetic resonance 
(CMR) imaging and biomarkers. Of these, the most 
promising is probably GLS with a value of around >−20% 
indicative of LV dysfunction postoperatively in patients 
referred for surgery.
In practice, a holistic approach is required. 
Conventional parameters of ESD and LVEF should 
be monitored scrupulously on a regular basis, at least 
annually. The addition of GLS can be useful in echo labs 
that are experienced in its use and in patients where 
image quality is good. Left atrial (LA) volumes are useful 
as if the LA is not enlarged then the MR is not chronic 
and severe. BNP measurements may be useful as if normal 
they provide reassurance that the LV is compensated. 
There should be a low threshold for symptomatic 
exercise testing to identify patients who are not truly 
asymptomatic and for confirmatory testing with CMR. 
There is emerging evidence that a regurgitant volume of 
>55 mL or a regurgitant fraction of >40% on CMR are 
makers of a worse prognosis.
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Abstract 1: Left ventricular mechano-temporal 
alterations during the apparent recovery of 
acute stress-induced (Tako-tsubo) 
cardiomyopathy
Janaki Srinivasan RDCS1, Konstantin Schwarz MD MRCP PhD1, Christopher J Neil 
MBBS PhD FRACP1, Caroline Scally MBBS MRCP1, John D Horowitz MD PhD FRACP 
FAHA2, Michael P Frenneaux MD FRCP FESC FMedSci1, Cristina Pislaru MD PhD3 and 
Dana K Dawson DM FRCP DPhil FESC1
1University of Aberdeen, Aberdeen, UK
2University of Adelaide, Adelaide, Australia
3Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
Aims
Tako-tsubo syndrome is an increasingly recognized cause 
of chest pain and occasionally of cardiogenic shock. 
However, the recovery course of this condition remains 
unresolved. Here, we describe the medium-term recovery 
in Tako-tsubo patients presenting predominantly with 
ST-elevation type ECG or malignant arrhythmias and 
with apical ballooning.
Methods and results
We prospectively recruited 47 patients with a clear-cut 
diagnosis of Tako-tsubo and 28 healthy controls of the same 
age, gender and cardiovascular co-morbidity distribution. 
Patients underwent comprehensive assessment of left 
ventricular (LV) myocardial deformation acutely and 
at 4-month follow-up. The patients’ mean age was 
66 years (range 41–87) and 92% were women. Most of the 
abnormal echocardiographic indices observed acutely in 
Tako-tsubo patients improved significantly at follow-up. 
However, significant mechano-temporal alterations 
characterizing both systole (global longitudinal strain, 
apical circumferential strain, both P < 0.01; left ventricular 
twist/twist rate and torsion, all P < 0.0001) and diastole 
(untwist rate and time to peak untwisting, all P < 0.001) 
persisted at 4-month follow-up when compared with 
controls, despite normalization of LV ejection fraction 
and end-diastolic volume.
Conclusion
In patients with the most clinically severe spectrum of 
Tako-tsubo cardiomyopathy, regional LV systolic and 
diastolic deformation abnormalities persist beyond the 
acute event, despite normalization of global LV function 
and size.
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Abstract 2: Right ventricular structure and 
function in veteran ultrarunners: is there 
evidence for chronic maladaptation?
Oliver J Rothwell1, Keith George1, John D Somauroo1, Rachel Lord2, 
Mike Stembridge2, Rob Shave2, Martin Hoffman3, Euan A Ashley4, Francois Haddad4, 
Thijs M H Eijsvogels1 and David Oxborough1
1Liverpool John Moores University, Liverpool, UK
2Cardiff Metropolitan University, Cardiff, UK
3University of California Davis Medical Centre, Sacramento, California, USA
4Stanford University, Stanford, California, USA
Purpose
It has been proposed that long-term participation in 
prolonged strenuous exercise may result in maladaptation 
of the right ventricle (RV). The aim of the study is 
to quantify size and function of the RV in a veteran 
population of ultrarunners and compare these findings 
to a sedentary control group. We hypothesize that 
ultrarunners will have larger RVs and impaired regional 
myocardial function.
Methods
40 ultrarunners and 24 age- and gender-matched 
sedentary controls (Table  1) volunteered to take part in 
the study. Conventional 2D and tissue Doppler (TDI) 
echocardiography were used to establish RV size and 
function. Structural data were scaled allometrically based 
on the rules of geometric similarity. Myocardial speckle 
tracking echocardiography was used to determine peak 
global and regional strain (ɛ) of the RV lateral free wall. 
Regional assessment of RV insertion points were made 
at the basal and apical anteroseptum and inferoseptum 
using longitudinal and circumferential left ventricular ɛ.
Results
All conventional RV parameters are presented in Table 2. 
Scaled structural parameters of RV size were significantly 
larger (P < 0.05) in ultrarunners compared to controls. 
Ultrarunners also had significantly higher RV fractional 
area change (FAC) and tissue Doppler (TDI) S′, E′ and A′. 
There were no significant differences in RV regional or 
global ɛ between the two groups. There was significantly 
higher basal circumferential ɛ at the RV insertion points 
in ultrarunners compared to controls, as well as higher 
longitudinal ɛ at the apical anteroseptum (Table 3).
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Table 1 Participant demographics.
Parameter Ultrarunners (n = 40) (mean ± s.d.) Controls (n = 24) (mean ± s.d.) P value
Age (years) 46 ± 8 46 ± 7 0.986
Gender (%) M = 82.5%, F = 17.5% M = 83.3%, F = 16.7% –
Height (cm) 177 ± 8 174 ± 7 0.112
Weight (kg) 71.3 ± 10.1 85 ± 14 <0.001
Body surface area 1.87 ± 0.16 2.02 ± 0.19 0.002
Training (years) 18 ± 12 4 ± 11 –
Training (h/week) 11 ± 4 1 ± 1 –
Number of marathons 61 ± 80 0 –
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This study demonstrates RV enlargement with higher 
conventional measures of function in veteran ultrarunners 
compared to age- and gender-matched controls. There is no 
evidence of maladaptation as demonstrated with normal 
and in some cases superior measures of global, regional and 
insertion point deformation. Our data suggest that regular 
exposure to endurance exercise has no negative consequences 
for the RV in the veteran ultrarunner population.
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Table 2 Conventional echocardiographic data of RV structural and functional parameters from ultrarunners and a sedentary 
age-matched control group.
Parameter Ultrarunners (n = 40) (mean ± s.d.) Controls (n = 24) (mean ± s.d.) P value
RVOTPLAX index (mm/(m2)0.5) 23 ± 3 21 ± 2.7 0.043
RVOT1 index (mm/(m2)0.5) 24 ± 3.4 21 ± 2.6 <0.001
RVOT2 index (mm/(m2)0.5) 18 ± 1.8 16 ± 1.9 0.003
RVD1 index (mm/(m2)0.5) 31 ± 3.8 26 ± 3.6 <0.001
RVD2 index (mm/(m2)0.5) 21 ± 3.4 16 ± 2.6 <0.001
RVD3 index (mm/(m2)0.5) 64 ± 5.4 55 ± 5.6 <0.001
RVD area index (cm2/m2) 13 ± 2.4 9 ± 2.3 <0.001
RVS area index (cm2/m2) 7 ± 1.9 5 ± 1.5 <0.001
RA volume index (mL/(m2)1.5) 25 ± 10.8 12 ± 4.9 <0.001
RVFAC (%) 50 ± 0.1 44 ± 0.1 0.013
TAPSE (mm) 24 ± 4 23 ± 3.6 0.321
TDI S′ (cm/s) 17 ± 2.9 13 ± 1.7 <0.001
S′ index ((cm/s)/cm) 1.95 ± 0.39 1.71 ± 0.27 0.011
TDI E′ (cm/s) 15 ± 3.2 12 ± 2.8 <0.001
E′ index ((cm/s)/cm) 1.83 ± 0.46 1.54 ± 0.40 0.019
TDI A′ (cm/s) 16 ± 4.3 13 ± 2.9 0.016
A′ index ((cm/s)/cm) 1.85 ± 0.55 1.69 ± 0.4 0.252
RA, right atrial; RV, right ventricular; RVD, RV dimensions 1 (base) 2 (mid) 3 (longitudinal); RVD and RVS area, RV diastolic and systolic area; RVFAC, RV 
fractional area change; RVOT1 and 2, RV outflow tract 1 (proximal) and 2 (distal); RVOTPLAX, RV outflow tract from parasternal long axis view; TAPSE, 
tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging during ventricular systole (S′) and during early (E′) and late (A′) ventricular diastole.
Table 3 Regional and global strain from the RV free wall and RV insertion points of ultrarunners and sedentary  
age-matched controls.
Parameter Ultrarunners (n = 40) (mean ± s.d.) Controls (n = 24) (mean ± s.d.) P value
RV basal ɛ (%) −27 ± 4.5 −29 ± 4.3 0.215
RV mid ɛ (%) −28 ± 3.8 −30 ± 4.5 0.174
RV apical ɛ (%) −32 ± 4.4 −32 ± 4.7 0.819
RV base to apex gradient (%) 4.3 ± 5.4 3.2 ± 5 0.396
LV circumferential   0.006
 Basal anterior septum ɛ (%) −26 ± 7.9 −21 ± 5.7 <0.001
 Basal septum ɛ (%) −25 ± 6 −16 ± 9.3  
LV radial   0.251
 Basal anterior septum ɛ (%) 39 ± 18.8 34 ± 17.3 0.259
 Basal septum ɛ (%) 43 ± 19 38 ± 17.9  
LV longitudinal   0.117
 Basal anterior septum ɛ (%) −19 ± 3.2 −18 ± 2.2 <0.001
 Apical anterior septum ɛ (%) −28 ± 6.8 −22 ± 4.3  
ɛ, indicates strain; LV, left ventricular; RV, right ventricular.
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Abstract 3: Feasibility, efficacy and safety of 
physiologist-led stress echocardiography in a 
rapid access chest pain setting
Reinette Hampson BSc1, Chris D Kinsey MD MRCP1, Sothinathan Gurunathan 
MD MRCP1,2, Anastasia Vamvakidou MD MRCP1,2, Nikolaos Karogiannis MD MRCP1 
and Roxy Senior MD DM FRCP FESC FACC1,2
1Department of Cardiology, Northwick Park Hospital, Harrow, UK
2Department of Cardiology, Royal Brompton Hospital, London, UK
Introduction
A rapid access chest pain clinic (RACPC) ideally should 
entail same day clinical assessment and investigation 
for the detection of coronary artery disease (CAD) to 
allow rapid management plan implementation. Ease 
of accessibility, rapid performance time and real-time 
interpretation make stress echocardiography (SE) the 
ideal test compared to other non-invasive imaging in the 
RACPC setting. SE has been shown to be more efficacious 
(both for diagnosis and prognosis), safe and more cost-
efficient than exercise ECG: it is the most widely used 
initial test for the assessment of CAD in the United 
Kingdom. We sought to assess whether physiologist-
led SE, which is inherently cost-saving, in the setting of 
RACPC is feasible, efficacious and safe.
Methods and results
Between May 2014 and May 2015, 768 consecutive 
patients (mean pre-test probability of CAD 36 ± 1.3%) 
referred from RACPC underwent SE, performed by a team 
of trained physiologists with physician availability and 
with all tests being interpreted by the lead consultant. In 
total, 675 (88%) patients had same day SE. Of the 768 
patients, 704 (92%) underwent treadmill exercise SE 
with dobutamine testing in the remainder. Diagnostic 
tests were achieved in 750 (98%) patients. Contrast was 
used in 725 (94%) patients. Significant adverse events 
were seen in only 2 (0.26%) patients. Of the 60 (8%) 
patients with inducible myocardial ischemia, 59 patients 
underwent coronary angiography. Flow-limiting CAD was 
demonstrated in 52 (88%) patients of whom 36 (69%) 
underwent revascularization. Of the 690 (92%) patients 
with normal SE, 2 (0.29%) suffered acute coronary 
syndrome over a follow-up period of at least 1 year.
Conclusion
Physiologist-led SE in the RACPC setting was highly 
feasible and safe, allowing rapid communication of SE 
results in almost 90% of patients and translated into a 
same day implementation of a management plan. SE 
also resulted in appropriate management, appropriate 
revascularization in those with positive SE and excellent 
outcome in those discharged with a negative SE. Given 
the high volume of referral to RACPC, physiologist-led 
SE is feasible, safe and efficacious, may be a cost-efficient 
alternative to other non-invasive diagnostic modalities.
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Abstract 4: Prognostic value of simultaneous 
stress echocardiography and carotid 
ultrasound in patients with suspected 
coronary artery disease
Shahram Ahmadvazir MD MRCP1,2,3,4, Benoy N Shah BSc MD MBBS MRCP FESC3,4,5, 
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1Department of Cardiovascular Medicine, Northwick Park Hospital, Harrow, UK
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3Cardiovascular Biomedical Research Unit, Imperial College London, London, UK
4Royal Brompton Hospital, London, UK
5University Hospital Southampton, Southampton, UK
Aims
The clinical significance of carotid disease in patients 
undergoing stress echocardiography (SE) for new-onset 
chest pain without known coronary artery disease 
(CAD) is unknown. We hypothesized that information 
of ischemia and atherosclerosis, which can be achieved 
simultaneously by ultrasound, may provide incremental 
prognostic information in these patients.
Methods
Consecutive patients with no previous history of CAD 
investigated with SE for suspected angina underwent 
carotid ultrasound (US) prospectively. Carotid plaque 
presence and burden were assessed. Patients were followed 
up for combined major adverse events (MAE) of all-cause 
mortality, non-fatal myocardial infarction and unplanned 
coronary revascularization.
Results
Out of 591 recruited patients, 580 (98%) (269 male (46%), 
mean age 59 ± 11  years) were available for follow-up. 
SE demonstrated myocardial ischemia in 12%, but 
prevalence of carotid plaques was 59%. During a mean 
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Incremental value of PTP-CAD, SE and CPB when used in a hierarchical 
sequence for predicting major adverse events (MAE) when CPB is added 
to PTP and SE. CAD, coronary artery disease; CPB, carotid plaque burden; 
PTP, pre-test probability; SE, stress echocardiography.
Figure 2
Incremental value of PTP-CAD, SE and CPB when used in a hierarchical 
sequence for predicting major adverse events (MAE) when SE is added to 
PTP and CPB. CAD, coronary artery disease; CPB, carotid plaque burden; 
PTP, pre-test probability; SE, stress echocardiography.
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follow-up of 1117 ± 361  days, 40 first MAE occurred. 
In the multivariable regression model, only abnormal 
SE (P < 0.0001) and carotid plaque burden (P < 0.0001) 
predicted MAE. MAE rate/year increased from 0.9% 
vs 1.97% vs 4.3% vs 9.7% in patients with no carotid 
plaque and normal SE vs presence of plaque and 
normal SE vs no plaque and abnormal SE vs presence 
of plaque and abnormal SE, respectively (P < 0.0001). 
In hierarchical analysis, plaque burden provided 
incremental prognostic value over pre-test probability 
of CAD and SE (Fig. 1), likewise SE was incremental to 
pre-test probability of CAD and plaque burden (P < 0.0001 
for both) (Fig. 2).
Conclusion
In patients with suspected stable angina without known 
CAD, simultaneous SE (for ischemia) and US (for 
atherosclerosis) provided synergistic prognostic value.
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Abstract 5: Long-term echocardiographic 
follow-up in transcatheter aortic valve 
implantation
Dan Bowen BSc, Shaun Robinson BSc MSc, Ugochukwu Ihekwaba MRCP, 
Karen Parker BSc, James Boyd, Cameron G Densem MD MRCP and Bushra S Rana 
MBBS FRCP
Cardiology Department, Papworth Hospital, Cambridge, UK
Purpose
Transcatheter aortic valve implantation (TAVI) is a well-
established procedure for treating severe aortic stenosis 
in elderly, non-surgical cases; however, long-term 
echocardiographic data is lacking. This study aims to 
collate several key echocardiographic parameters over 
long-term follow-up and highlight incidence rates of 
valvular degeneration.
Methods
49 patients were selected who had undergone TAVI 
(Sapien; Sapien XT; Sapien 3) and were followed up within 
the Papworth physiologist-led valve service (Table  4). 
Retrospective analysis was performed on standard 2D/
Doppler-derived echo data and compared during three 
follow-up stages (FU1 1 year post TAVI, FU2 2 years post, 
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Table 4 Baseline characteristics (n = 49).
Parameter Value




Coronary artery disease 39 (80)
Previous myocardial infarction 5 (10)
Previous open heart surgery 37 (76)
Previous cerebrovascular accident 7 (14)
COPD 3 (6)
Atrial fibrillation 13 (27)
Anticoagulation 13 (27)
Antiplatelet 42 (86)
Trans-femoral TAVI 41 (84)
TAVI size 23 mm 9 (18)
TAVI size 26 mm 20 (41)
TAVI size 29 mm 20 (41)
Values are mean ± s.d. or n (%).
Table 5 Mean echo parameters (baseline to FU2).
 FU1 (n = 49) FU2 (n = 47) FU3 (n = 26) Change FU1–FU3 (%) P value (FU1–FU2; FU1–FU3; FU2–FU3)
PPG (mmHg) 21.8 ± 13 22.2 ± 12.6 23.4 ± 15.4 7.5 0.91; 0.72; 0.83
MPG (mmHg) 11.5 ± 7.2 12.1 ± 7.3 13.3 ± 9.3 15.5 0.45; 0.80; 0.65
AVA (cm2) 1.70 ± 0.59 1.61 ± 0.50 1.69 ± 0.51 −0.4 0.19; 0.70; 0.56
AVAi (cm2/m2) 0.87 ± 0.34 0.84 ± 0.24 0.87 ± 0.27 0 0.48; 0.71; 0.53
VR 0.5 ± 0.15 0.45 ± 0.12 0.5 ± 0.15 0 0.11; 0.55; 0.17
EF (%) 50.8 ± 9.1 50.6 ± 9.6 54.3 ± 7.81 7.0 0.35; 0.12; 0.04
SVi (mL/m2) 41.4 ± 14 38.7 ± 10.3 39.7 ± 8.5 −4.1 0.21; 0.52; 0.56
sPAP (mmHg) 36.1 ± 9.6 33.5 ± 9.27 34.3 ± 7.1 −5.0 0.32; 0.76; 0.77
Values are mean ± s.d. or n (%). Statistical analysis by Students paired t-test. Bold indicates the mean value.
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26 patients reached FU3 (53%), with a total mortality rate of 
8%. There were no notable changes seen across traditional 
mean prosthetic valve Doppler measurements from FU1 
to FU3 (P = >0.05), while LVEF improved slightly between 
FU2 and FU3 (51–54%; P = 0.04). Secondary analysis 
comparing different valve sizes indicated that the smaller 
valve size (23 mm) was slightly more obstructive, reflected 
by higher peak/mean pressure gradients and lower aortic 
valve area (AVA), AVA index and velocity ratio (Figs 3, 4, 
5, 6 and 7). At FU1, the incidence of paravalvular leak 
(PVL) was 53%, of which 16% of cases were considered 
more significant (≥moderate) (Fig.  8). A 3% increase in 
incidence of significant PVL was noted from FU1 to FU3, 
while the 29 mm valve size showed the greatest increase 
in incidence of PVL from FU1 to FU3 (10–21%) (Fig. 9). 
3 patients were identified to have developed thrombus 
formation on their valve (6%), with significantly 
obstructive valvular parameters, which then resolved 
somewhat upon commencing anticoagulation therapy.
Conclusion
Our data show a range of traditional prosthetic valve 
Doppler values, which may be used to guide sonographers 
when assessing different TAVI valves and highlight rates 
of significant valvular degeneration. Further studies with 
larger sample sizes than the present study are required to 
further assess the validity of these findings.
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Figure 3
PPG by valve size (FU1–FU3).
Figure 4
MPG by valve size (FU1–FU3).
Figure 5
AVA by valve size (FU1–FU3).
Figure 6
AVAi by valve size (FU1–FU3).
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Figure 7
VR by valve size (FU1–FU3).
Figure 8
Paravalvular leak incidence from FU1 to FU3 (n).
Figure 9
Paravalvular leak incidence from FU1 to FU3 accounting for valve size.
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Abstract 6: The CHA2DS2VASc risk score 
appropriately risk stratifies patients prior to 
atrial fibrillation ablation and reduces the 
requirement for trans-esophageal 
echocardiography
Charlotte Atkinson MSc, Jonathan Hinton MRCP, Edmund B Gaisie BMBS, 
Dhrubo J Rakhit PhD FRCP FACC, Arthur M Yue DM FRCP, Paul R Roberts MD FRCP 
and Benoy N Shah BSc MD MBBS MRCP FESC
University Hospital of Southampton NHS Foundation Trust, Southampton, UK
Background
Prior to atrial fibrillation (AF) ablation, current 
recommendations suggest patients undergo trans-
esophageal echocardiography (TOE) to exclude left 
atrial appendage (LAA) thrombus. Patients undergoing 
AF ablation are usually anticoagulated thus making 
the presence of thrombus unlikely. This study aimed to 
determine whether the CHA2DS2VASc scoring system can 
be used for risk stratification to identify patients that do 
not require TOE prior to AF ablation.
Methods
In this single-center retrospective cohort study, local 
institutional and primary care databases and electronic 
patient records were searched to identify patients that 
had undergone TOE prior to AF ablation and also 
correlated with cath lab records of these patients. Patient 
demographics, CHA2DS2VASc score, TOE findings and 
anticoagulation status were collected retrospectively.
Results
Over a 7-year period (2008–2014), 346 patients underwent 
TOE prior to proposed AF ablation of which 14 patients 
were excluded due to incomplete data, leaving a total 
sample size of 332 patients (age 57 ± 10 years; 74% male). 
CHA2DS2VASc scores of 0, 1, 2 and >2 were found in 39, 
34, 15 and 12% of patients respectively. The prevalence of 
LAA thrombus was 0.6% (2 patients) and these 2 patients 
had risk scores of 2 and 4. No patients with a score of 0 or 
1 had LAA thrombus.
Conclusions
Patients that are classed as low risk by the CHA2DS2VASc 
score (score of 0 or 1) do not require a pre-ablation TOE 
to screen for LAA thrombus provided they have been on 
anticoagulation with a stable therapeutic INR. This would 
lead to a significant reduction in health care expenditures 
by reducing unnecessary TOE requests and also thereby 
improve patient experience.
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Abstract 7: The role of speckle tracking strain 
imaging in assessing left ventricular response 
to cardiac resynchronization therapy in 
responders and non-responders
Dean Thomas MSc BSc HCPC, Pat Phen MBBS PhD FRCP, Jonathan Sibley, 
Sarah Fergey and Paul Russhard MSc BSc
The Essex Cardiothoracic Centre, Basildon and Thurrock University Hospital, Basildon, Essex, UK
Background
Despite advancements in research, cardiac resynchronization 
therapy (CRT) response is still defined clinically by symptomatic 
improvement. Speckle tracking strain imaging with its ability 
to evaluate left ventricular (LV) dysfunction and dyssynchrony 
would provide an ideal parameter to assess CRT response.
Aim
To validate speckle tracking strain imaging for assessing 
the difference in LV dysfunction and dyssynchrony 
between responders and non-responders following 3 
months of CRT. To examine the relationship between 
symptomatic response and physiological response to CRT.
Methods
In 28 patients, echocardiography and Minnesota Living 
with Heart Failure Questionnaire (MLHFQ) was performed 
at baseline and following 3 months of CRT. Response to CRT 
was defined as a ≥15% reduction in MLHFQ score between 
baseline and 3 months. Speckle tracking strain imaging was 
used to assess LV dysfunction and dyssynchrony.
Results
At follow-up, 79% of patients were classified as responders 
with 21% as non-responders to CRT. A significant 
difference in baseline global longitudinal strain (GLS) 
was found between responders and non-responders 
(mean 8.2 ± 2.72% vs 6.22 ± 1.73%; P < 0.05). There 
was an insignificant difference in GLS, time to peak 
radial and longitudinal strain between responders and 
non-responders following 3 months of CRT (P > 0.05). 
The percentage of biventricular pacing was greater in 
responders vs non-responders (mean 96.2 ± 4.1% vs 
88.8 ± 13.2%; P = 0.03). 3.8% of the change in symptomatic 
response is accounted for by change in GLS.
Conclusion
Both responders and non-responders have a mechanical 
response to CRT. GLS can predict response to CRT. 
Assessment of biventricular pacing at follow-up is 
important factor influencing response.
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